SCHEMBL721579

SCHEMBL721579

Cc1ccc2oc(C(Cl)C3CCCCC3)c(C)c2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.41
RAB9A P51151 5/20 0.38
ALDH1A1 P00352 1/20 0.36
KMT2A Q03164 2/20 0.35
NR2E3 Q9Y5X4 1/20 0.35
F12 P00748 1/20 0.35
MAPT P10636 1/20 0.35
HTT P42858 1/20 0.35
KCNH2 Q12809 1/20 0.34
TSHR P16473 1/20 0.33
NCOA3 Q9Y6Q9 1/20 0.33
CSNK2A2 P19784 1/20 0.33
CSNK2B P67870 1/20 0.33
CSNK2A1 P68400 1/20 0.33
HRH4 Q9H3N8 1/20 0.32
GABRP O00591 1/20 0.32
GABRD O14764 1/20 0.32
GABRA1 P14867 1/20 0.32
GABRB1 P18505 1/20 0.32
GABRG2 P18507 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL721218 0.88 MCL1 (0.43) NPC1RAB9AALDH1A1MAPTKCNH2
SCHEMBL718379 0.86 NPC1 (0.52) NPC1RAB9AALDH1A1KMT2AMAPT
SCHEMBL717053 0.84 NPC1 (0.45) NPC1RAB9AALDH1A1KMT2ANR2E3
SCHEMBL718939 0.84 RAB9A (0.54) NPC1RAB9AALDH1A1KMT2AMAPT
SCHEMBL721329 0.83 HRH4 (0.36) NPC1RAB9AALDH1A1HRH4
SCHEMBL716824 0.83 NPC1 (0.48) NPC1RAB9AALDH1A1KMT2AMAPT
SCHEMBL719533 0.78 NPC1 (0.41) NPC1RAB9AALDH1A1KMT2AKCNH2
SCHEMBL718571 0.78 L3MBTL1 (0.50) NPC1RAB9AALDH1A1KMT2A
SCHEMBL721192 0.76 MCL1 (0.45) NPC1RAB9AALDH1A1KMT2AMAPT
SCHEMBL718925 0.73 NPC1 (0.55) NPC1RAB9AALDH1A1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP NPC1 902/4885RAB9A 2454/4885ALDH1A1 504/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP NPC1 902/4885RAB9A 2454/4885ALDH1A1 504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.